Trial Profile
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs MK 8189 (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Oct 2022 Primary endpoint (Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4) has not been met according to results presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
- 18 Oct 2022 Results presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
- 31 Jan 2018 Status changed from active, no longer recruiting to completed.